Glycemic Objectives of Women With Gestational Diabetes Mellitus
NCT ID: NCT02478762
Last Updated: 2018-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
5 participants
INTERVENTIONAL
2015-03-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, the investigators want to compare the FGH of newborn of GDM women randomized to a group reaching the Canadian Diabetes Association recommended blood glucose objectives treatment (fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L) to a group reaching lower blood glucose objectives (fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early Screening for Gestational Diabetes Mellitus
NCT01026675
Glucose Levels in Early Pregnancy and Feto-maternal Outcome
NCT04756102
Intrapartum Glycemic Control in GDMA2
NCT05647798
Daily Versus Every Other Day Glucose Monitoring in Gestational Diabetes Mellitus
NCT04857073
Home Versus Hospital Care in Glucose Monitoring of Gestational Diabetes and Mild Gestational Hyperglycemia
NCT01441518
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal glycemic control
GDM women in this group will reach glycemic objectives recommended by the Canadian Diabetes Association: fasting: 5.3 mmol/L and 2-hour after meals: 6.7 mmol/L.
Normal glycemic control
Use diet, physical exercise of insulins to reach normal glycemic control.
Low glycemic control
GDM women in this group will reach lower glycemic objectives than those recommended by the Canadian Diabetes Association: fasting: 4.8 mmol/L and 2-hour after meals: 5.9 mmol/L.
Low glycemic control
Use diet, physical exercise of insulins to reach low glycemic control.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Normal glycemic control
Use diet, physical exercise of insulins to reach normal glycemic control.
Low glycemic control
Use diet, physical exercise of insulins to reach low glycemic control.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* received education on gestational diabetes mellitus,
* able to read and understand French.
Exclusion Criteria
* treatment interfering woth glucose metabolism,
* deficit may hinder the understanding of the study.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Université de Sherbrooke
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jean-Luc Ardilouze
Endocrinologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Luc Ardilouze, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Université de Sherbrooke
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14-160
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.